berberine has been researched along with Colorectal Neoplasms in 38 studies
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Individuals aged 18-75 years who had at least one but no more than six histologically confirmed colorectal adenomas that had undergone complete polypectomy within the 6 months before recruitment were recruited and randomly assigned (1:1) to receive berberine (0·3 g twice daily) or placebo tablets via block randomisation (block size of six)." | 9.34 | Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. ( Cao, HL; Cao, XC; Chen, HM; Chen, YX; Dou, XT; Fang, JY; Gao, QY; Kang, Q; Li, N; Liu, SD; Liu, ZJ; Ren, JL; Sheng, JQ; Song, YY; Sun, XM; Wang, BM; Xiao, B; Xu, HZ; Yang, XN; Zhu, W; Zou, TH; Zou, XP, 2020) |
| "To elucidate the underly molecular mechanisms of berberine in colorectal cancer from a perspective of epigenetics, and tried to explore the role of lincROR-Wnt/β-catenin molecular axis in the berberine induced the anti-tumour activity in colorectal cancer." | 8.31 | Berberine inhibits tumour growth in vivo and in vitro through suppressing the lincROR-Wnt/β-catenin regulatory axis in colorectal cancer. ( Fu, WM; Li, SY; Shi, CJ; Zhang, JF, 2023) |
| " Berberine can reduce colorectal adenoma recurrence and inhibit colorectal carcinogenesis." | 8.12 | Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora. ( Chang, J; Geng, Z; Hao, X; Liu, J; Tan, X; Wang, Z; Yan, S, 2022) |
| "Berberine (BBR) is one of isoquinoline alkaloids from Coptidis Rhizoma and possesses extensive pharmacological activities, including anti-colorectal cancer (CRC) activity." | 7.96 | Berberine inhibits proliferation and induces G0/G1 phase arrest in colorectal cancer cells by downregulating IGF2BP3. ( Huang, L; Li, X; Liu, X; Ma, W; Xiao, Y; Xu, M; Ye, X; Yu, M; Zhang, Y, 2020) |
| "To investigate the effect and explore its possible mechanisms of epidermal growth factor receptor(EGFR) expression in macrophages on the anti-cancer effect of berberine (BER) on the growth of colorectal cancer." | 7.81 | [Effect and mechanism of EGFR expression in macrophages on the anti-cancer effect of berberine on colorectal cancer]. ( Cao, H; Lu, L; Lu, N; Tong, Z; Zhang, M, 2015) |
| "Berberine(BBR) is a kind of isoquinoline alkaloids extracted from the rhizomes of Coptis chinensis Franch." | 6.82 | Efficacy and safety of berberine in preventing recurrence of colorectal adenomas: A systematic review and meta-analysis. ( Cao, Z; Du, S; Fang, S; Guo, S; Su, X; Wei, W; Yang, Y, 2022) |
| "Berberine has shown anti-inflammatory properties which make it an ideal option in order to prevent inflammation-associated cancers." | 6.66 | Targeting of oncogenic signaling pathways by berberine for treatment of colorectal cancer. ( Asemi, Z; Hallajzadeh, J; Maleki Dana, P; Mansournia, MA; Mobini, M; Sharifi, M; Yousefi, B, 2020) |
| "The increasing incidence of colorectal cancer (CRC) has become a major global public health burden." | 5.91 | Berberine promotes IGF2BP3 ubiquitination by TRIM21 to induce G1/S phase arrest in colorectal cancer cells. ( Chai, X; Chen, L; Gong, X; Gui, Z; Li, J; Li, M; Li, X; Lu, F; Ma, H; Ma, Z; Tang, X; Ye, X, 2023) |
| "Colorectal carcinogenesis and progression are related to the gut microbiota and the tumor immune microenvironment." | 5.91 | Berberine might block colorectal carcinogenesis by inhibiting the regulation of B-cell function by Veillonella parvula. ( Chen, H; Chen, Y; Cui, Y; Fang, J; Gao, Q; Kang, Z; Li, X; Liu, Q; Qian, Y; Wang, Z; Zhao, L; Zhou, C; Zou, T, 2023) |
| "Human colorectal cancer (CRC), a highly malignant and metastatic carcinoma, is resistant to many present anticancer therapies." | 5.56 | Berberine inhibits proliferation and migration of colorectal cancer cells by downregulation of GRP78. ( Gong, C; Hu, X; Li, Z; Lu, D; Wang, C; Xu, Y; Yang, J; Zhu, J; Zong, L, 2020) |
| "Berberine is an alkaloid isolated from the Chinese herbal medicine Huanglian, and has long been used as an antibiotic." | 5.40 | Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. ( Cai, Y; Huang, P; Jiang, W; Luo, R; Shi, Y; Sun, Y; Xia, Q, 2014) |
| " Individuals aged 18-75 years who had at least one but no more than six histologically confirmed colorectal adenomas that had undergone complete polypectomy within the 6 months before recruitment were recruited and randomly assigned (1:1) to receive berberine (0·3 g twice daily) or placebo tablets via block randomisation (block size of six)." | 5.34 | Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. ( Cao, HL; Cao, XC; Chen, HM; Chen, YX; Dou, XT; Fang, JY; Gao, QY; Kang, Q; Li, N; Liu, SD; Liu, ZJ; Ren, JL; Sheng, JQ; Song, YY; Sun, XM; Wang, BM; Xiao, B; Xu, HZ; Yang, XN; Zhu, W; Zou, TH; Zou, XP, 2020) |
| "To elucidate the underly molecular mechanisms of berberine in colorectal cancer from a perspective of epigenetics, and tried to explore the role of lincROR-Wnt/β-catenin molecular axis in the berberine induced the anti-tumour activity in colorectal cancer." | 4.31 | Berberine inhibits tumour growth in vivo and in vitro through suppressing the lincROR-Wnt/β-catenin regulatory axis in colorectal cancer. ( Fu, WM; Li, SY; Shi, CJ; Zhang, JF, 2023) |
| " Berberine can reduce colorectal adenoma recurrence and inhibit colorectal carcinogenesis." | 4.12 | Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora. ( Chang, J; Geng, Z; Hao, X; Liu, J; Tan, X; Wang, Z; Yan, S, 2022) |
| "Berberine (BBR) is one of isoquinoline alkaloids from Coptidis Rhizoma and possesses extensive pharmacological activities, including anti-colorectal cancer (CRC) activity." | 3.96 | Berberine inhibits proliferation and induces G0/G1 phase arrest in colorectal cancer cells by downregulating IGF2BP3. ( Huang, L; Li, X; Liu, X; Ma, W; Xiao, Y; Xu, M; Ye, X; Yu, M; Zhang, Y, 2020) |
| " In the azoxymethane initiated and dextran sulfate sodium (AOM/DSS) promoted colorectal carcinogenesis mouse model, berberine treated mice showed a 60% reduction in tumor number (P = 0." | 3.81 | Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. ( Colburn, NH; Hou, W; Hua, B; Jia, L; Li, W; Lin, H; Matter, MS; Saud, SM; Young, MR, 2015) |
| "To investigate the effect and explore its possible mechanisms of epidermal growth factor receptor(EGFR) expression in macrophages on the anti-cancer effect of berberine (BER) on the growth of colorectal cancer." | 3.81 | [Effect and mechanism of EGFR expression in macrophages on the anti-cancer effect of berberine on colorectal cancer]. ( Cao, H; Lu, L; Lu, N; Tong, Z; Zhang, M, 2015) |
| "Berberine is a plant extract widely used in clinical practice." | 3.01 | Berberine and health outcomes: An umbrella review. ( Chen, T; Li, X; Li, Z; Ma, J; Tian, Y; Wang, Y; Wen, Y; Xu, Q; Yan, J, 2023) |
| "Berberine(BBR) is a kind of isoquinoline alkaloids extracted from the rhizomes of Coptis chinensis Franch." | 2.82 | Efficacy and safety of berberine in preventing recurrence of colorectal adenomas: A systematic review and meta-analysis. ( Cao, Z; Du, S; Fang, S; Guo, S; Su, X; Wei, W; Yang, Y, 2022) |
| "Berberine has shown anti-inflammatory properties which make it an ideal option in order to prevent inflammation-associated cancers." | 2.66 | Targeting of oncogenic signaling pathways by berberine for treatment of colorectal cancer. ( Asemi, Z; Hallajzadeh, J; Maleki Dana, P; Mansournia, MA; Mobini, M; Sharifi, M; Yousefi, B, 2020) |
| "The increasing incidence of colorectal cancer (CRC) has become a major global public health burden." | 1.91 | Berberine promotes IGF2BP3 ubiquitination by TRIM21 to induce G1/S phase arrest in colorectal cancer cells. ( Chai, X; Chen, L; Gong, X; Gui, Z; Li, J; Li, M; Li, X; Lu, F; Ma, H; Ma, Z; Tang, X; Ye, X, 2023) |
| "Colorectal carcinogenesis and progression are related to the gut microbiota and the tumor immune microenvironment." | 1.91 | Berberine might block colorectal carcinogenesis by inhibiting the regulation of B-cell function by Veillonella parvula. ( Chen, H; Chen, Y; Cui, Y; Fang, J; Gao, Q; Kang, Z; Li, X; Liu, Q; Qian, Y; Wang, Z; Zhao, L; Zhou, C; Zou, T, 2023) |
| "Berberine (BBR) has anticancer activity." | 1.62 | Berberine inhibits colorectal tumor growth by suppressing SHH secretion. ( Huang, TM; Shen, ZQ; Tan, WF; Wang, J, 2021) |
| "Human colorectal cancer (CRC), a highly malignant and metastatic carcinoma, is resistant to many present anticancer therapies." | 1.56 | Berberine inhibits proliferation and migration of colorectal cancer cells by downregulation of GRP78. ( Gong, C; Hu, X; Li, Z; Lu, D; Wang, C; Xu, Y; Yang, J; Zhu, J; Zong, L, 2020) |
| "Jatrorrhizine (JAT) is a natural protoberberine alkaloid, possesses detoxification, bactericidal and hypoglycemic activities." | 1.51 | Jatrorrhizine inhibits colorectal carcinoma proliferation and metastasis through Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition. ( Dian, LL; Gao, XY; Liang, ZS; Phyo, AT; Qasim, M; Sun, YF; Sun, ZX; Wang, P; Yang, SQ, 2019) |
| "Colorectal cancer is the third leading cause of cancer-related deaths in the word." | 1.48 | Coptisine-induced apoptosis in human colon cancer cells (HCT-116) is mediated by PI3K/Akt and mitochondrial-associated apoptotic pathway. ( Han, B; Huang, T; Jiang, P; Li, X; Li, Z; Ye, X; Yu, Y, 2018) |
| "The prognosis of colorectal cancer (CRC) is seriously affected by high intestinal mucosal permeability accompanied by increasing tumor load." | 1.48 | Effects of berberine on tumor growth and intestinal permeability in HCT116 tumor-bearing mice using polyamines as targets. ( Li, TM; Liu, B; Wang, GX; Wu, YY; Zang, LQ, 2018) |
| "Accumulating evidence links colorectal cancer (CRC) with the intestinal microbiota." | 1.42 | Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. ( An, HF; Chen, HM; Chen, HY; Fang, JY; Hong, J; Li, M; Ma, X; Qin, WX; Shen, N; Sun, TT; Weng, YR; Yu, J; Yu, TC; Yu, YN; Zhao, HJ, 2015) |
| "Berberine is an alkaloid isolated from the Chinese herbal medicine Huanglian, and has long been used as an antibiotic." | 1.40 | Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. ( Cai, Y; Huang, P; Jiang, W; Luo, R; Shi, Y; Sun, Y; Xia, Q, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.26) | 29.6817 |
| 2010's | 14 (36.84) | 24.3611 |
| 2020's | 22 (57.89) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, S | 1 |
| Guo, S | 1 |
| Du, S | 1 |
| Cao, Z | 1 |
| Yang, Y | 2 |
| Su, X | 1 |
| Wei, W | 1 |
| Othman, MS | 1 |
| Al-Bagawi, AH | 1 |
| Obeidat, ST | 1 |
| Fareid, MA | 1 |
| Habotta, OA | 1 |
| Moneim, AEA | 1 |
| Yan, S | 1 |
| Chang, J | 1 |
| Hao, X | 1 |
| Liu, J | 2 |
| Tan, X | 1 |
| Geng, Z | 1 |
| Wang, Z | 2 |
| Ni, L | 1 |
| Sun, P | 1 |
| Ai, M | 1 |
| Kong, L | 1 |
| Xu, R | 1 |
| Li, J | 4 |
| Li, SY | 1 |
| Shi, CJ | 1 |
| Fu, WM | 1 |
| Zhang, JF | 1 |
| Nathani, S | 3 |
| Mishra, R | 3 |
| Katiyar, P | 3 |
| Sircar, D | 3 |
| Roy, P | 3 |
| Gui, Z | 1 |
| Li, X | 7 |
| Chen, L | 1 |
| Ma, Z | 1 |
| Tang, X | 1 |
| Gong, X | 1 |
| Chai, X | 1 |
| Lu, F | 1 |
| Li, M | 2 |
| Ma, H | 3 |
| Ye, X | 4 |
| Li, Z | 3 |
| Wang, Y | 4 |
| Xu, Q | 1 |
| Ma, J | 1 |
| Yan, J | 1 |
| Tian, Y | 1 |
| Wen, Y | 1 |
| Chen, T | 1 |
| Chen, H | 2 |
| Ye, C | 1 |
| Wu, C | 1 |
| Zhang, J | 2 |
| Xu, L | 2 |
| Wang, X | 3 |
| Xu, C | 1 |
| Guo, Y | 1 |
| Yao, Q | 1 |
| Iloki Assanga, SB | 1 |
| Lewis Luján, LM | 1 |
| McCarty, MF | 1 |
| Qian, Y | 1 |
| Kang, Z | 1 |
| Zhao, L | 1 |
| Zhou, C | 1 |
| Gao, Q | 2 |
| Liu, Q | 1 |
| Cui, Y | 3 |
| Chen, Y | 1 |
| Zou, T | 1 |
| Fang, J | 1 |
| Ibrahim, D | 1 |
| Khater, SI | 1 |
| Abdelfattah-Hassan, A | 1 |
| Alqahtani, LS | 1 |
| Metwally, AS | 1 |
| Bazeed, SM | 1 |
| Elgamal, A | 1 |
| Sheraiba, NI | 1 |
| Hussein, EM | 1 |
| Ali Alasmary, F | 1 |
| Salem, GA | 1 |
| Ali, M | 1 |
| Mahfouz, H | 1 |
| He, X | 1 |
| Cui, J | 1 |
| Abuduaini, N | 1 |
| Huang, Y | 1 |
| Tang, L | 1 |
| Wang, W | 1 |
| Zhang, Y | 3 |
| Lu, W | 1 |
| Feng, B | 1 |
| Huang, J | 1 |
| Tan, S | 1 |
| Ou, Y | 1 |
| Huang, S | 1 |
| Chen, S | 1 |
| Xue, X | 1 |
| Li, ZS | 1 |
| Yang, GY | 1 |
| Song, Y | 1 |
| Pan, Y | 1 |
| Ma, Y | 1 |
| Hu, S | 1 |
| Wen, A | 1 |
| Jia, Y | 1 |
| Rodriguez, LM | 1 |
| Tull, MB | 1 |
| Benante, K | 1 |
| Khan, SA | 1 |
| Cao, Y | 1 |
| Jovanovic, B | 1 |
| Richmond, E | 1 |
| Umar, A | 1 |
| Bergan, R | 1 |
| Wu, K | 1 |
| Gong, C | 1 |
| Hu, X | 1 |
| Xu, Y | 1 |
| Yang, J | 1 |
| Zong, L | 1 |
| Wang, C | 1 |
| Zhu, J | 1 |
| Lu, D | 1 |
| Chen, YX | 1 |
| Gao, QY | 1 |
| Zou, TH | 1 |
| Wang, BM | 1 |
| Liu, SD | 1 |
| Sheng, JQ | 1 |
| Ren, JL | 1 |
| Zou, XP | 1 |
| Liu, ZJ | 1 |
| Song, YY | 1 |
| Xiao, B | 1 |
| Sun, XM | 1 |
| Dou, XT | 1 |
| Cao, HL | 1 |
| Yang, XN | 1 |
| Li, N | 1 |
| Kang, Q | 1 |
| Zhu, W | 1 |
| Xu, HZ | 1 |
| Chen, HM | 2 |
| Cao, XC | 1 |
| Fang, JY | 2 |
| Kwon, S | 1 |
| Chan, AT | 1 |
| Guan, X | 1 |
| Zheng, X | 1 |
| Vong, CT | 1 |
| Zhao, J | 1 |
| Xiao, J | 1 |
| Zhong, Z | 1 |
| Hallajzadeh, J | 1 |
| Maleki Dana, P | 1 |
| Mobini, M | 1 |
| Asemi, Z | 1 |
| Mansournia, MA | 1 |
| Sharifi, M | 1 |
| Yousefi, B | 1 |
| Liu, X | 2 |
| Yu, M | 1 |
| Xu, M | 1 |
| Xiao, Y | 2 |
| Ma, W | 1 |
| Huang, L | 1 |
| Shen, ZQ | 1 |
| Wang, J | 1 |
| Tan, WF | 1 |
| Huang, TM | 1 |
| Han, B | 2 |
| Jiang, P | 1 |
| Yu, Y | 1 |
| Huang, T | 2 |
| Wang, H | 1 |
| Guan, L | 1 |
| Lai, M | 1 |
| Wen, X | 1 |
| Wu, YY | 1 |
| Li, TM | 1 |
| Zang, LQ | 1 |
| Liu, B | 1 |
| Wang, GX | 1 |
| Dai, W | 2 |
| Mu, L | 2 |
| Li, Y | 3 |
| Chen, P | 2 |
| Xie, H | 2 |
| Wang, P | 1 |
| Gao, XY | 1 |
| Yang, SQ | 1 |
| Sun, ZX | 1 |
| Dian, LL | 1 |
| Qasim, M | 1 |
| Phyo, AT | 1 |
| Liang, ZS | 1 |
| Sun, YF | 1 |
| Cai, Y | 1 |
| Xia, Q | 1 |
| Luo, R | 1 |
| Huang, P | 1 |
| Sun, Y | 1 |
| Shi, Y | 1 |
| Jiang, W | 1 |
| Li, W | 1 |
| Hua, B | 1 |
| Saud, SM | 1 |
| Lin, H | 1 |
| Hou, W | 1 |
| Matter, MS | 1 |
| Jia, L | 1 |
| Colburn, NH | 1 |
| Young, MR | 1 |
| Ji, Q | 1 |
| Ye, N | 1 |
| Sui, H | 1 |
| Zhou, L | 1 |
| Zhu, H | 1 |
| Fan, Z | 1 |
| Cai, J | 1 |
| Li, Q | 1 |
| Su, YH | 1 |
| Tang, WC | 1 |
| Cheng, YW | 1 |
| Sia, P | 1 |
| Huang, CC | 1 |
| Lee, YC | 1 |
| Jiang, HY | 1 |
| Wu, MH | 1 |
| Lai, IL | 1 |
| Lee, JW | 1 |
| Lee, KH | 1 |
| Yu, YN | 1 |
| Yu, TC | 1 |
| Zhao, HJ | 1 |
| Sun, TT | 1 |
| Chen, HY | 1 |
| An, HF | 1 |
| Weng, YR | 1 |
| Yu, J | 1 |
| Qin, WX | 1 |
| Ma, X | 1 |
| Shen, N | 1 |
| Hong, J | 1 |
| Lu, N | 1 |
| Tong, Z | 1 |
| Zhang, M | 1 |
| Lu, L | 1 |
| Cao, H | 1 |
| Yi, L | 1 |
| Li, L | 1 |
| Wang, M | 1 |
| Tian, C | 1 |
| He, K | 1 |
| Liu, SW | 1 |
| Li, HR | 1 |
| Ma, WB | 1 |
| Pan, TC | 1 |
| Zhu, LY | 1 |
| Ye, WC | 1 |
| Wang, LW | 1 |
| Chen, LX | 1 |
| Piyanuch, R | 1 |
| Sukhthankar, M | 1 |
| Wandee, G | 1 |
| Baek, SJ | 1 |
| Kang, MR | 1 |
| Chung, IK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-controlled, Multicenter, Prospective Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas[NCT02226185] | Phase 2/Phase 3 | 1,108 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study[NCT04543643] | Phase 3 | 288 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for berberine and Colorectal Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of berberine in preventing recurrence of colorectal adenomas: A systematic review and meta-analysis.
Topics: Adenoma; Berberine; Colorectal Neoplasms; Coptis chinensis; Humans | 2022 |
Berberine and health outcomes: An umbrella review.
Topics: Berberine; Colorectal Neoplasms; Constipation; Humans; Lipids | 2023 |
Targeting beta-catenin signaling for prevention of colorectal cancer - Nutraceutical, drug, and dietary options.
Topics: Anthocyanins; Berberine; beta Catenin; Colorectal Neoplasms; Cyclooxygenase 2; Diet; Dietary Supplem | 2023 |
Preventive effects of chemical drugs on recurrence of colorectal adenomas: systematic review and Bayesian network meta-analysis.
Topics: Adenoma; Berberine; Colorectal Neoplasms; Humans; Network Meta-Analysis; Randomized Controlled Trial | 2024 |
Targeting of oncogenic signaling pathways by berberine for treatment of colorectal cancer.
Topics: Animals; Berberine; Colorectal Neoplasms; Humans; Signal Transduction | 2020 |
2 trials available for berberine and Colorectal Neoplasms
| Article | Year |
|---|---|
A Phase I Trial of Berberine in Chinese with Ulcerative Colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Biopsy; China; Coli | 2020 |
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study.
Topics: Adenoma; Adolescent; Adult; Aftercare; Aged; Antineoplastic Agents, Phytogenic; Berberine; Chemoprev | 2020 |
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study.
Topics: Adenoma; Adolescent; Adult; Aftercare; Aged; Antineoplastic Agents, Phytogenic; Berberine; Chemoprev | 2020 |
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study.
Topics: Adenoma; Adolescent; Adult; Aftercare; Aged; Antineoplastic Agents, Phytogenic; Berberine; Chemoprev | 2020 |
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study.
Topics: Adenoma; Adolescent; Adult; Aftercare; Aged; Antineoplastic Agents, Phytogenic; Berberine; Chemoprev | 2020 |
31 other studies available for berberine and Colorectal Neoplasms
| Article | Year |
|---|---|
Antitumor Activity of Zinc Nanoparticles Synthesized with Berberine on Human Epithelial Colorectal Adenocarcinoma (Caco-2) Cells through Acting on Cox-2/NF-kB and p53 Pathways.
Topics: Adenocarcinoma; Animals; Apoptosis; bcl-2-Associated X Protein; Berberine; Caco-2 Cells; Caspase 3; | 2022 |
Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora.
Topics: Animals; Azoxymethane; Berberine; Carcinogenesis; Cell Transformation, Neoplastic; Colitis; Colorect | 2022 |
Berberine inhibited the formation of metastasis by intervening the secondary homing of colorectal cancer cells in the blood circulation to the lung and liver through HEY2.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Berberine; beta Catenin; Cadherins; Cell Line | 2022 |
Berberine inhibits tumour growth in vivo and in vitro through suppressing the lincROR-Wnt/β-catenin regulatory axis in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Berberine; beta Catenin; Cell Line, Tumor; Cell Prolifera | 2023 |
Zinc Acts Synergistically with Berberine for Enhancing Its Efficacy as an Anti-cancer Agent by Inducing Clusterin-Dependent Apoptosis in HT-29 Colorectal Cancer Cells.
Topics: Annexin A5; Apoptosis; Berberine; Cell Line, Tumor; Cell Proliferation; Clusterin; Colonic Neoplasms | 2023 |
Zinc Acts Synergistically with Berberine for Enhancing Its Efficacy as an Anti-cancer Agent by Inducing Clusterin-Dependent Apoptosis in HT-29 Colorectal Cancer Cells.
Topics: Annexin A5; Apoptosis; Berberine; Cell Line, Tumor; Cell Proliferation; Clusterin; Colonic Neoplasms | 2023 |
Zinc Acts Synergistically with Berberine for Enhancing Its Efficacy as an Anti-cancer Agent by Inducing Clusterin-Dependent Apoptosis in HT-29 Colorectal Cancer Cells.
Topics: Annexin A5; Apoptosis; Berberine; Cell Line, Tumor; Cell Proliferation; Clusterin; Colonic Neoplasms | 2023 |
Zinc Acts Synergistically with Berberine for Enhancing Its Efficacy as an Anti-cancer Agent by Inducing Clusterin-Dependent Apoptosis in HT-29 Colorectal Cancer Cells.
Topics: Annexin A5; Apoptosis; Berberine; Cell Line, Tumor; Cell Proliferation; Clusterin; Colonic Neoplasms | 2023 |
Zinc Acts Synergistically with Berberine for Enhancing Its Efficacy as an Anti-cancer Agent by Inducing Clusterin-Dependent Apoptosis in HT-29 Colorectal Cancer Cells.
Topics: Annexin A5; Apoptosis; Berberine; Cell Line, Tumor; Cell Proliferation; Clusterin; Colonic Neoplasms | 2023 |
Zinc Acts Synergistically with Berberine for Enhancing Its Efficacy as an Anti-cancer Agent by Inducing Clusterin-Dependent Apoptosis in HT-29 Colorectal Cancer Cells.
Topics: Annexin A5; Apoptosis; Berberine; Cell Line, Tumor; Cell Proliferation; Clusterin; Colonic Neoplasms | 2023 |
Zinc Acts Synergistically with Berberine for Enhancing Its Efficacy as an Anti-cancer Agent by Inducing Clusterin-Dependent Apoptosis in HT-29 Colorectal Cancer Cells.
Topics: Annexin A5; Apoptosis; Berberine; Cell Line, Tumor; Cell Proliferation; Clusterin; Colonic Neoplasms | 2023 |
Zinc Acts Synergistically with Berberine for Enhancing Its Efficacy as an Anti-cancer Agent by Inducing Clusterin-Dependent Apoptosis in HT-29 Colorectal Cancer Cells.
Topics: Annexin A5; Apoptosis; Berberine; Cell Line, Tumor; Cell Proliferation; Clusterin; Colonic Neoplasms | 2023 |
Zinc Acts Synergistically with Berberine for Enhancing Its Efficacy as an Anti-cancer Agent by Inducing Clusterin-Dependent Apoptosis in HT-29 Colorectal Cancer Cells.
Topics: Annexin A5; Apoptosis; Berberine; Cell Line, Tumor; Cell Proliferation; Clusterin; Colonic Neoplasms | 2023 |
Berberine promotes IGF2BP3 ubiquitination by TRIM21 to induce G1/S phase arrest in colorectal cancer cells.
Topics: Animals; Berberine; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Mice; RNA, Messenger | 2023 |
Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut microbiota-mediated lysophosphatidylcholine.
Topics: Animals; Berberine; Carcinogenesis; Colorectal Neoplasms; Diet, High-Fat; Gastrointestinal Microbiom | 2023 |
Berberine might block colorectal carcinogenesis by inhibiting the regulation of B-cell function by Veillonella parvula.
Topics: Animals; Berberine; Carcinogenesis; Colorectal Neoplasms; Humans; Tumor Microenvironment; Veillonell | 2023 |
Prospects of new targeted nanotherapy combining liponiosomes with berberine to combat colorectal cancer development: An in vivo experimental model.
Topics: Animals; Apoptosis; Berberine; Colorectal Neoplasms; Cyclooxygenase 2; Mammals; Models, Theoretical; | 2023 |
Berberrubine is a novel and selective IMPDH2 inhibitor that impairs the growth of colorectal cancer.
Topics: Animals; Berberine; Cell Line; Colorectal Neoplasms; Humans; IMP Dehydrogenase; Mice; Protein Isofor | 2023 |
Berberine inhibits proliferation and migration of colorectal cancer cells by downregulation of GRP78.
Topics: Apoptosis; Berberine; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Endoplasmic Reticulum | 2020 |
Extracting the benefits of berberine for colorectal cancer.
Topics: Adenoma; Antineoplastic Agents, Phytogenic; Aspirin; Berberine; Cardiovascular Diseases; Case-Contro | 2020 |
Combined effects of berberine and evodiamine on colorectal cancer cells and cardiomyocytes in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Berberine; Caco-2 Cells; Cardiotoxicity; Co | 2020 |
Berberine inhibits proliferation and induces G0/G1 phase arrest in colorectal cancer cells by downregulating IGF2BP3.
Topics: Animals; Apoptosis; Berberine; Biomarkers, Tumor; Cell Proliferation; Colorectal Neoplasms; Female; | 2020 |
Berberine inhibits colorectal tumor growth by suppressing SHH secretion.
Topics: Animals; Antineoplastic Agents; Berberine; Cell Line, Tumor; Colorectal Neoplasms; Hedgehog Proteins | 2021 |
Coptisine-induced apoptosis in human colon cancer cells (HCT-116) is mediated by PI3K/Akt and mitochondrial-associated apoptotic pathway.
Topics: Animals; Apoptosis; Berberine; Cell Movement; Cell Proliferation; Cell Survival; Colorectal Neoplasm | 2018 |
The Effects of Berberine on the Gut Microbiota in Apc
Topics: Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; Bacteria; Berberine; beta Cateni | 2018 |
Effects of berberine on tumor growth and intestinal permeability in HCT116 tumor-bearing mice using polyamines as targets.
Topics: Animals; Antineoplastic Agents, Phytogenic; Berberine; Colorectal Neoplasms; Dose-Response Relations | 2018 |
Berberine Promotes Apoptosis of Colorectal Cancer via Regulation of the Long Non-Coding RNA (lncRNA) Cancer Susceptibility Candidate 2 (CASC2)/AU-Binding Factor 1 (AUF1)/B-Cell CLL/Lymphoma 2 (Bcl-2) Axis.
Topics: Apoptosis; Berberine; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Disease Progression; | 2019 |
Long non‑coding RNA CASC2 enhances berberine‑induced cytotoxicity in colorectal cancer cells by silencing BCL2.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Berberine; Cell Line, Tumor; Cell Movemen | 2019 |
Jatrorrhizine inhibits colorectal carcinoma proliferation and metastasis through Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Berberine; beta Catenin; Cell Proliferation; Cell Surviva | 2019 |
Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2014 |
Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Azoxymethane; Berberine; Carcinogenesis; Caspase | 2015 |
Berberine Inhibits Invasion and Metastasis of Colorectal Cancer Cells via COX-2/PGE2 Mediated JAK2/STAT3 Signaling Pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Berberine; Cell Line, Tumor; Cell Movement; Colon; Color | 2015 |
Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Berberine; Cell Line, Tumor; Colorectal Neoplasms; C | 2015 |
Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment.
Topics: Adenoma; Animals; Berberine; Blotting, Western; Cell Transformation, Neoplastic; Colorectal Neoplasm | 2015 |
[Effect and mechanism of EGFR expression in macrophages on the anti-cancer effect of berberine on colorectal cancer].
Topics: Animals; Antineoplastic Agents; Apoptosis; Berberine; Caspase 3; Colorectal Neoplasms; Genes, erbB-1 | 2015 |
Coptisine from Rhizoma Coptidis Suppresses HCT-116 Cells-related Tumor Growth in vitro and in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Araceae; Berberine; Cell Proliferation; Colore | 2017 |
[Berberine activates volume-sensitive chloride channel in human colorectal carcinoma cells].
Topics: Berberine; Cell Line, Tumor; Chloride Channels; Colorectal Neoplasms; Humans; Nitrobenzoates; Osmoti | 2011 |
Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells.
Topics: Activating Transcription Factor 3; Alkaloids; Apoptosis; Berberine; Biological Products; Blotting, W | 2007 |
Down-regulation of DNA topoisomerase IIalpha in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine.
Topics: Alkaloids; Antigens, Neoplasm; Antineoplastic Agents; Berberine; Colorectal Neoplasms; DNA Topoisome | 2002 |